Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: A randomized, controlled trial

Hormone and Metabolic Research

Volumn 40, Issue 4, 2008, Pages 281-285

  Anastasilakis, A D ^a,e   Goulis, D G ^b   Polyzos, S A ^a   Gerou, S ^c   Koukoulis, G ^d   Kita, M ^a   Avramidis, A ^a  

^a Aristotle University of Thessaloniki   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Laboratories Analysis   (Greece)

^d UNIVERSITY OF THESSALY   (Greece)

^e NONE   (Greece)

Author keywords

Bone markers; Osteoprotegerin; RANKL; Risedronate; Teriparatide

Indexed keywords

CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 1 N TERMINAL PROPEPTIDE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OSTEOPENIA; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

AGED; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; CALCIUM; COLLAGEN TYPE I; ETIDRONIC ACID; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPROTEGERIN; RANK LIGAND; TERIPARATIDE;

EID: 42149104383     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1046787     Document Type: Article

References (34)

1. Sambrook P, Cooper C. Osteoporosis. Lancet 2006; 367: 2010-2018
2. Wolinsky F, Fitzgerald J, Stump T. The effect of hip fracture on mortality, hospitalization, and functional status: a prospective study. Am J Public Health 1997; 87: 398-403
3. Ray N, Chan J, Thamer M, Melton LR. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12: 24-35
4. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19: 80-100
5. Nenonen A, Cheng S, Ivaska K, Alatalo S, Lehtimaki T, Schmidt-Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Sievanen H, Vuori I, Vaananen H, Halleen J. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with othet markers of bone turnover. J Bone Miner Res 2005; 20: 1804-1812
6. Rosen H, Moses A, Garber J, Iloputaife I, Ross D, Lee S, Greenspan S. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000; 66: 100-103
7. Hodsman A, Bauer D, Dempster D, Dian L, Hanley D, Harris S, Kendler D, MacClung M, Miller P, Olszynski W, Orwoll E, Yuen C. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005; 26: 688-703
8. Orwoll E, Scheele W, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman J, Clancy A, Gaich G. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18: 9-17
9. Body J, Gaich G, Scheele W, Kulkarni P, Miller P, Peretz A, Dore R, Correa-Rotter R, Papaioannou A, Cumming D, Hodsman AB. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87: 4528-4535
10. Black D, Greenspan S, Ensrud K, Palermo L, MacGowan J, Lang T, Garnero P, Bouxsein M, Bilezikian J, Rosen C. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349: 1207-1215
11. Chen P, Satterwhite J, Licata A, Lewiecki E, Sipos A, Misurski D, Wagman R. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005; 20: 962-970
12. Eastell R, Krege J, Chen P, Glass E, Reginster J. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 2006; 22: 61-66
13. Gori F, Hofbauer L, Dunstan C, Spelsberg T, Khosla S, Riggs B. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 2000; 141: 4768-4776
14. Rogers A, Richard E. Circulating osteoprotegerin and receptor activator for nuclear factor κB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005; 90: 6323-6331
15. Chen D, Sarikaya N, Gunn H, Martin S, Young J. ELISA methodology for detection of modified osteoprotegerin in clinical studies. Clin Chem 2001; 47: 747-749
16. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle W, Lacey D, Riggs B. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003; 111: 1221-1230
17. Valleala H, Mandelin J, Laasonen L, Koivula M, Risteli J, Konttinen Y. Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. Eur J Endocrinol 2003; 148: 527-530
18. Alvarez L, Peris P, Guanabens N, Vidal S, Ros I, Pons F, Filella X, Monegal A, Munoz-Gomez J, Ballesta A. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis Rheum 2003; 48: 824-828
19. Martini G, Gennari L, Merlotti D, Salvadori S, Fraud M, Campagna S, Avanzati A, Paola V De, Valleggi F, Nuti R. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. Bone 2007; 40: 457-463
20. Dobnig H, Hoflauer L, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int 2006; 17: 693-703
21. Buxton E, Yao W, Lane N. Changes in serum receptor activator of nuclear factor-κB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human patathyroid hormone (1-34). J Clin Endocrinol Metab 2004; 89: 3332-3336
22. Sasaki N, Kusano E, Ando Y, Yano K, Tsuda E, Asano Y. Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. Nephrol Dial Transplant 2001; 16: 479-482
23. Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, Mayr A, Jocher J, Xu Q, Pietschmann P, Teitelbaum S, Smolen J, Willeit J. Soluble RANKL and risk of nontraumatic fracture. JAMA 2004; 291: 1108-1113
24. Mezquita-Raya P, Higuera M de la, Garda D, Alonso G, Ruiz-Requena M, Dios Luna J de, Escobar-Jimenez F, Munoz-Torres M. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int 2005; 16: 1368-1374
25. Khosla S, Arrighi H, Melton IL, Atkinson E, O'Fallon W, Dunstan C, Riggs B. Correlates of osteoprotegerin levels in women and men. Osteoporos Int 2002; 13: 394-399
26. Szulc P, Hofbauer L, Heufelder A, Roth S, Delmas P. Osteoprotegetin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 2001; 86: 3162-3165
27. Rogers A, Saleh G, Hannon R, Greenfield D, Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 2002; 87: 4470-4475
28. Fahrleitner-Pammer A, Dobnig H, Piswanger-Soelkner C, Bonelli C, Dimai H, Leb G, Obermayer-Pietsch B. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. Wien Klin Wochenschr 2003; 115: 291-297
29. Indridason O, Franzson L, Sigurdsson G. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int 2005; 16: 417-423
30. Liu J, Zhao H, Ning G, Zhao Y, Chen Y, Zhang Z, Sun L, Xu M, Chen J. Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75. Calcif Tissue Int 2005; 76: 1-6
31. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, Yamada Y. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999; 14: 518-527
32. Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 2003; 32: 681-686
33. Gonnage-Yared M, Fares F, Semaan M, Khalife S, Jambart S. Circulating osteoprotegetin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. Clin Endocrinol (Oxf) 2006; 64: 652-658
34. Oh E, Rhee E, Oh K, Lee W, Baek K, Yoon K, Kang M, Yun E, Park C, Choi M, Yoo H, Park S. Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women. Metabolism 2005; 54: 49-54